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Highly pathogenic avian influenza (HPAI) viruses constitute a pandemic threat and the
development of effective vaccines is a global priority. Sixty adults were recruited into a ran-
domized clinical trial and were intramuscularly immunized with two virosomal vaccine H5N1
(NIBRG-14) doses (21 days apart) of 30μg HA alone or 1.5, 7.5 or 30μg HA adjuvanted with
Matrix M. The kinetics and longevity of the serological responses against NIBRG-14 were
determined by haemagglutination inhibition (HI), single radial haemolysis (SRH), microneu-
tralization (MN) and ELISA assays. The cross-H5 clade responses in sera were determined
by HI and the antibody-secreting (ASC) cell ELISPOT assays. The protective efficacy of the
vaccine against homologous HPAI challenge was evaluated in ferrets.
Results
The serological responses against the homologous and cross-reactive strains generally
peaked one week after the second dose, and formulation with Matrix M augmented the
responses. The NIBRG-14-specific seroprotection rates fell significantly by six months and
were low against cross-reactive strains although the adjuvant appeared to prolong the lon-
gevity of the protective responses in some subjects. By 12 months post-vaccination, nearly
all vaccinees had NIBRG-14-specific antibody titres below the protective thresholds. The
Matrix M adjuvant was shown to greatly improve ASC and serum IgG responses following
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vaccination. In a HPAI ferret challenge model, the vaccine protected the animals from febrile
responses, severe weight loss and local and systemic spread of the virus.
Conclusion





HPAI virus subtype H5N1 continues to be a serious threat to animal and human health [1].
Human cases of H5N1 are rare, however infection results in high fatality rates. Between 2003
and January 2015, the World Health Organization (WHO) has reported 694 cases of human
H5N1 infections in 16 countries with 402 deaths [2]. H5N1 infections have mainly been
detected in the Asian continent, with Indonesia (197 cases), Egypt (203 cases), Viet Nam (127
cases), Cambodia (56 cases), China (47 cases) and Thailand (25 cases) reporting the highest
number of cases [2]. The first known fatal case of human H5N1 in North America was
imported to Canada from Asia in 2014, highlighting the potential for trans-continental spread
of these viruses.
Vaccination is the main intervention to reduce morbidity and mortality associated with
influenza H5N1 infections. The Influenza H5N1 virus is a poor immunogen compared with
seasonal strains or pandemic 2009 H1N1 and humans do not have pre-existing immunity to
H5 viruses. Human clinical trials have shown that at least two doses of H5N1 vaccines formu-
lated with effective adjuvants are needed to elicit protective immune responses [3]. Very few
adjuvants are currently used in human vaccines with aluminium salts being the most widely
used, but these do not augment the response to H5N1. Novel adjuvants such as proprietary oil-
in-water emulsions (AS03, MF59) have shown great potential for antigen dose-sparing and
augmenting immune response to homologous and cross-reactive strains after H5 vaccination
(reviewed by [3]). Immune stimulating complex (ISCOM) technology is another promising
adjuvant with a good safety profile in humans and has been shown to augment the antibody
and cellular immune response after vaccination (summarized in [4]). ISCOMs are formed by
strong cholesterol binding to Quillaja saponins (Quillaja saponariaMolina) forming 12nm
rings, which in turn are held together by lipid based hydrophobic interactions to form spherical
particles 40nm in diameter. Matrix M is a third generation ISCOM and is a mix of Matrix C,
which is a highly active but slightly reactogenic sapononin, and Matrix A, which is a weaker
but well tolerated saponin [4]. In a phase I clinical trial involving 60 healthy adults, we have
demonstrated that a Matrix M-adjuvanted H5N1 (NIBRG-14) virosomal vaccine has an
acceptable safety profile, capacity for antigen dose sparing and induce a balanced Th1/Th2
antibody and cellular responses, including multifunctional T cells [5–7]. Furthermore, this vac-
cine elicited protection against HPAI H5N1 virus challenge in murine pre-clinical studies [6,
8]. In the current study, we report in detail the early kinetics of the homologous and cross-H5
clade immune response and the long-term effectiveness of the NIBRG-14 H5N1 influenza vac-
cine formulated with or without the Matrix M adjuvant in humans. Furthermore, we tested the
protective efficacy of the NIBRG-14 H5N1 vaccine against challenge with highly pathogenic
H5N1 Vaccine Study in Humans and Ferrets
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avian influenza virus infection in a ferret infection model, which is a well-established model for
influenza research (reviewed by [9]).
Materials and Methods
Study participants and ethics statement
A phase I open label clinical trial was conducted in 60 healthy adult subjects (20–49 years old)
at the Haukeland University Hospital, Bergen, Norway. Prior to being enrolled in the study, all
participants provided written informed consent and were screened for normal haematology,
biochemistry and immunology parameters. The full study demographics and exclusion criteria
were reported earlier [5]. The study was approved by the local regional ethics committee of
Northern Norway (Regional komité for medisinsk og helsefaglig forskningsetikk, Nord-Norge,
REK Nord) and the Norwegian Medicines Agency and registered in the European Clinical Tri-
als Database (EudraCT no. 2008-006940-20), the WHO Initiative for Vaccine Research [10]
and National Institute for Health (NIH, Clinical trials.gov, Study: NCT00868218).
Vaccine and Matrix M adjuvant
The virus strain used for the vaccine is the reverse genetics NIBRG-14 strain, which is a reas-
sortant between the human A/Vietnam/1194/2004 (H5N1) and A/Puerto Rico/8/34 (H1N1)
(PR8) strains. The influenza virosomal vaccine was produced under Good Manufacturing
Practice by Crucell Berna Biotech (the Netherlands) as described previously [5]. The vaccine
(1.5, 7.5, or 30μg HA) was formulated with Matrix-M (50μg, Novavax, MD, USA) in phosphate
buffered saline (PBS) and filled into single use syringes (0.5ml per syringe) and stored at 4°C
until used.
Study design
We recruited 60 healthy adult volunteers (mean age 31 years old, 60% female, between
24.03.2009 and 23.06.2009) and the clinical investigator randomly allocated subjects into four
groups of 15 by drawing lots. The random allocation was concealed from all except the clinical
investigator until completion of the immunological assays. A dose escalation study was per-
formed where five subjects from each group were vaccinated twice, 21 days (±1) apart with the
virosomal H5N1 vaccine alone (30μg HA) or with vaccine (1.5, 7.5 or 30μg HA) formulated
with Matrix-M (50μg) adjuvant. This was followed by immunization of the remaining 10 sub-
jects from each group using the same vaccination schedule. A sample size of 15 was determined
by the clinical investigator as the minimum number needed to detect statistically significant
differences between the vaccine groups. A group size of 15 is common for first in humans,
phase I trials, however, a larger phase II/III trial would be required with higher statistical power
to provide further safety and immunogenicity data. The inclusion and exclusion criteria were
reviewed for each subject before administration of each dose of vaccine. Blood samples were
collected at 7, 14 and 21 days after each dose of vaccine and 180 and 365 days after the first vac-
cination. All blood (serum) samples were aliquoted and stored at -80°C until used in serological
assays as described previously [5]. Peripheral blood mononuclear cells (PBMCs) were har-
vested from Cell Separation Tubes (CPT, BD Biosciences) according to manufacturer’s instruc-
tions and used immediately in the ELISPOT assays.
Serological assays
All serum samples collected pre- and post-vaccination were tested in the haemagglutination
inhibition (HI) assay using the egg grown viruses A/Vietnam/1194/2004 (NIBRG-14, clade 1),
H5N1 Vaccine Study in Humans and Ferrets
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A/Indonesia/05/2005 (IBCDC-RG2, clade 2, subclade 1.3.2), A/turkey/Turkey/1/2005
(NIBRG-23, clade 2, subclade 2.2.1) and A/Cambodia/R0405050/2007 (NIBRG-88, clade 1,
subclade 1) as described previously [5]. The microneutralization (MN) and single radial hemo-
lysis (SRH) assays were performed against the homologous NIBRG-14 strain by Health Protec-
tion England, United Kingdom and Istituto Superiore di Sanita, Italy, respectively as described
before [11, 12]. All serum samples were run at least in duplicate in the serological assays.
The antibody secreting cell (ASC) response
The number of ASCs were evaluated by Enzyme Linked ImmunoSPOT assay (ELISPOT) as
described previously [13] with some modifications. Briefly, 96 well ELISPOT plates (Multi-
screen HA, Millipore) were coated with 2μg/ml A/Vietnam/1194/2004 (NIBRG-14, clade 1),
A/turkey/Turkey/1/2005 (NIBRG-23, clade 2, subclade 2.2.1), A/Cambodia/R0405050/2007
(NIBRG-88, clade 1, subclade 1) or A/Anhui/1/05 (RG6, clade 2, subclade 3.4) whole virus
overnight at 4°C. PBMCs (5×105 cells) were added to duplicate wells and incubated overnight
at 37°C and 5% CO2. Antibodies (IgG, IgA or IgM) secreted by the PBMCs were detected by
incubation with goat anti-human class-specific antibodies for 2h at room temperature. After
development with the substrate (9-amino 3-ethyl carbazole), the number of spots was calcu-
lated using an ELISPOT Immunoscan reader and the ImmunoSpot software (CTL-Europe
GmbH, Germany).
Memory B cell response
The NIBRG-14-specific IgG memory B cell (Bmem) response after vaccination was quantified
by ELISPOT as described elsewhere [14]. The ELISPOT assay was conducted as described
above with NIBRG-14 virosomes coated on the ELISPOT plates. Results are presented as virus-
specific IgG memory B cells per 1 × 106 PBMCs.
The serum IgG response
The homologous influenza-specific IgG antibodies were quantified by Enzyme Linked Immo-
nosorbant assay (ELISA) as previously described [15]. Briefly, ELISA plates were coated with
2μg/ml influenza virosomal vaccine and capture goat anti-human IgG antibodies (1mg/ml)
overnight at 4°C. Serially diluted human sera and immunoglobulin standards were incubated
for 2h at room temperature followed by one hour incubation with biotin-conjugated goat anti-
human IgG (1/1000 dilution) and one hour incubation with extravidin peroxidase (1/1000).
The antibody concentrations were calculated using the IgG standards and linear regression of
the log-transformed readings.
Vaccination and viral challenge of ferrets
Adult male ferrets (Mustela putorius furo) at 7–9 months of age were randomly assigned to
one of five study groups (10 ferrets per group). A sample size of 10 was determined by the chief
investigator as the minimum number needed to detect statistically significant differences
between the vaccine groups. Ferrets were housed in open pens after vaccination and then trans-
ferred to individual cages prior to challenge. Animals were fed twice daily with ferret breeding
and maintenance diet. All ferrets were seronegative as determined by HI assays (HI titres<10)
to currently circulating influenza H3, H1 and B strains. The study was approved by National
Institute for Biological Standards and Control (NIBSC) Animal Welfare and Ethical Review
Body and experiments carried out during day time according to the UK Home Office License
regulations.
H5N1 Vaccine Study in Humans and Ferrets
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Animals were immunized by the intramuscular route with two NIBRG-14 virosomal vac-
cine doses containing 1.5, 7.5 or 30μg HA, 14 days apart, (n = 10) formulated with 50μg Matrix
M or vaccine without the adjuvant (30μg HA, n = 10). Control animals received PBS (n = 10).
Animals were bled from the jugular vein pre vaccination and 12 days after each immunization.
Serum samples were stored at -20°C until testing in the serological assays. Fourteen days after
the second immunization, animals were sedated with 0.2mL/kg of Ketamine/Xylazine and
challenged by intranasally administering A/Vietnam/1203/2004 live virus (106 egg infectious
dose (EID)50 in 0.4mL PBS/BSA). Following challenge all animals were monitored for fever
and weight change.
Three days post-challenge, four animals from each group were sacrificed and the lungs,
nasal turbinates, brains, olfactory bulbs and spleens were collected. The remaining animals
were observed for clinical signs of disease until 14 days post- challenge, when surviving animals
were exsanguinated under terminal anaesthesia. Animals whose condition reached the moder-
ate severity limit of the study were exsanguinated under terminal anaesthesia. The challenge
study was conducted under enhanced BSL-3 conditions.
Virus recovery from nasal washings and tissue samples from ferrets
Immediately after collection, ferret tissues were weighed and homogenized in L15 medium
containing penicillin (1000 IU) and streptomycin (100μg/ml). Homogenates were clarified by
centrifugation and aliquots frozen at -70°C. Nasal washings, and clarified tissue homogenates
were inoculated undiluted or diluted (10-1–10-8) into Madin-Darby Canine Kidney (MDCK)
cells in 96 well tissue culture plates and incubated at 35°C for three days. Aliquots of medium
from each well were transferred to wells of U-well microtitre plates and the presence of repli-
cating virus detected using 0.7% turkey blood. Virus titres were calculated by the method of
Spearman-Karber [16]. The limit of detection in Tissue Culture Infectious Dose (TCID)50
assay for the ferret tissue samples was 101.63 TCID50/ml of homogenate.
Statistics
Statistical analysis was performed by GraphPad Prism version 6 for Mac OS X (GraphPad Soft-
ware, Ja Jolla, CA, USA) and the longitudinal data were analyzed by R 3.1.1 (R Core team). In
the human clinical trial, the MN, SRH, HI and serum IgG titres and ASC and Bmem responses
between the virosomal alone and adjuvanted vaccine groups were assessed by ANOVA fol-
lowed by Dunnetts multiple comparisons test. The longitudinal serological and ELISA data
were analyzed using a linear mixed model (assuming compound symmetry) with the unadju-
vanted (30-) dose a reference and time as a continuous variable. The longitudinal data were
analyzed only up to day 42 post-vaccination as too few sample were available beyond this time
point. Spearman rank correlation coefficient (r) values (adjusted for multiple comparisons)
were calculated to determine the correlation between the NIBRG-14-specific and cross-H5
clade serological responses. In the ferret challenge model, the virus titres recovered from nasal
washings and tissue samples and body temperatures between the vaccinated and control
groups were assesses by ANOVA (with Dunnett’s multiple comparisons test). p-values<0.05
were regarded as significant in all statistical tests.
Results
In this study, we investigated the early kinetics and the long-term persistence of the serological
responses induced by a candidate H5N1 vaccine formulated with or without the Matrix M
adjuvant. Serological responses were determined against both the homologous vaccine as well
as clade 1 and 2 H5N1 strains. Fig 1 shows the CONSORT flowchart of the clinical trial and the
H5N1 Vaccine Study in Humans and Ferrets
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CONSORT checklist (S1 File), N3CRs Arrive guidelines (S2 File) and study protocol (S3 File)
are provided as supporting information. The protective efficacy of the vaccine formulations
against challenge with HPAI virus was tested in a ferret infection model.
Microneutralization response to vaccination
Fig 2 shows the kinetics (Fig 2A) and long-term (Fig 2B) MN responses in humans after vac-
cination. A seroprotective MN response was defined as a MN titre80 [17]. No pre-vaccina-
tion neutralizing antibodies were detected in any of the subjects. MN responses were
detectable by day 7 in all groups (except the adjuvanted 1.5μg HA group) with one subject
each from the adjuvanted 7.5μg and 30μg HA groups having a protective antibody response.
At day 14, higher MN geometric mean titres (GTMT) were observed in the adjuvanted 30μg
HA (GMT = 25) and 7.5μg HA (GMT = 13) groups compared with the virosomal alone
group (GMT = 9), however, when considering only the responding subjects, the differences
were not statistically significant. The response plateaued to day 21 with at least one subject
Fig 1. CONSORT flowchart. In total, 65 adult subjects were assessed for eligibility and 60 were included in the study (mean age 31 years old, 60% female).
Prior to being enrolled in the study, all participants provided written informed consent and were screened for normal haematology, biochemistry and
immunology parameters. The 60 volunteers were randomised into four groups and were immunised twice, 21 days (±1) apart with the virosomal H5N1
vaccine alone (30μg HA) or with vaccine (1.5, 7.5 or 30μg HA) formulated with Matrix-M (50μg) adjuvant. Blood samples were collected at 7, 14 and 21 days
after each dose of vaccine and 180 and 365 days after the first vaccination.
doi:10.1371/journal.pone.0131652.g001
H5N1 Vaccine Study in Humans and Ferrets
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Fig 2. The kinetics and long-termmicroneutralization response after vaccination. The kinetics (A) and long-term (B) microneutralization (MN) antibody
response to the homologous vaccine strain A/Vietnam/1194/2004 (NIBRG-14) after vaccination with two doses (21 ±1 days apart) of inactivated virosomal
H5N1 vaccine alone (30μg HA, blue) or 1.5 (red), 7.5 (green) or 30μg HA (black) adjuvanted with Matrix-M (50μg). The sampling day after vaccination is
shown on the x-axis. Each symbol represents the geometric mean MN titre for one individual participant, with the group geometric mean titre and 95%
confidence interval presented. The dotted line indicates the protective MN titre of 80.
doi:10.1371/journal.pone.0131652.g002
H5N1 Vaccine Study in Humans and Ferrets
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from each vaccine group having protective neutralizing responses. The second immunization
augmented the MN response in all vaccine groups. On day 28, 38% of vaccinees in the 1.5μg
HA group and 64% in the adjuvanted 30μg HA group had MN titres 80. In comparison,
only 15% of volunteers in the virosomal alone group had protective MN titres at day 28. By
day 35, an increase in the MN GMTs was observed in the adjuvanted 1.5μg HA (GMT = 95,
58% seroprotected) and 30μg HA (GMT = 163, 85% seroprotected) groups while titres
slightly decreased in the other two vaccine groups. When considering only the responding
subjects, the adjuvanted 30μg HA group had significantly higher GMTs compared with the
non-adjuvanted group at days 28, 35 and 42 post-vaccination. On day 42, a dose-dependent
response was observed in the adjuvant groups with between 46% and 60% of subjects having
protective neutralizing antibody titres, whilst only 14% in the virosomal alone group were
seroprotected.
Fig 2B shows the long-term NIBRG-14-specific MN responses after vaccination. At 6
months post-vaccination (day 180), only three persons in the adjuvanted 30μg HA group and
one from the 7.5μg HA group had protective titres while none from the 1.5μg HA or virosomal
alone groups had seroprotective titres. An antibody response was detected in 64% to 90% of
subjects given an adjuvanted vaccine while only 29% of volunteers in the unadjuvanted vaccine
group had a detectable antibody response. At 12 months post-vaccination, one person in the
adjuvanted 30μg HA group had a protective MN response and antibody was still detectable in
66% to 77% of the subjects vaccinated with an adjuvanted vaccine and in 35% of subjects in the
unadjuvanted vaccine group.
Single radial haemolysis antibody response to vaccination
Fig 3A shows the kinetics of the SRH response to the homologous vaccine strain NIBRG-14. A
seroprotective SRH response was defined as a SRH zone area25mm2. No SRH antibodies
were detected pre vaccination apart from two volunteers in the 7.5 μg HA adjuvanted group
who had very low SRH zone areas of 6 and 9mm2. The SRH responses started to increase from
day 7 post-first vaccination with 3 out of 15 subjects in the 30μg HA adjuvanted group having
SRH zone areas25 mm2. The SRH titres continued to increase by day 14-post first vaccina-
tion, with 4 subjects in the 30μg HA adjuvanted group and 1–2 subjects in other groups having
SRH zone areas25 mm2. By day 21, 7 of 15 subjects (47%) in the adjuvanted 30μg HA group
had SRH zone areas25 mm2, whereas only 2 to 4 vaccinees had protective antibody titres in
the other vaccine groups. The second immunization augmented the SRH titres in all of the vac-
cine and by day 28, all of the subjects in the adjuvanted 7.5μg HA and 30 μg HA groups had
SRH zone areas25 mm2, whilst high SRH titres were also detected in the adjuvanted 1.5μg
HA (85% protected) and virosomal alone groups (54% protected). When considering only the
responding subjects, the adjuvanted 7.5μg HA and 30 μg HA groups had significantly higher
GMT zone areas compared with the non-adjuvanted group at day 28. Similarly at day 35, the
7.5μg HA group had significantly higher SRH zone areas compared with the non-adjuvanted
group. Among the volunteers that received an adjuvanted vaccine, between 0% and 13% failed
to elicit a SRH response at day 42, whilst the number of non-responders was 43% in the non-
adjuvanted group.
Fig 3B shows the SRH titres at 6 and 12 months post-vaccination. At 6 months post-vacci-
nation, a majority of subjects (61% to 80%) who had received an adjuvanted vaccine had SRH
zone area25mm2, whilst 38% of volunteers in the virosomal alone group had protective SRH
titres. The response decreased by 12 months post-vaccination where SRH titres could only be
detected in 12% to 42% of subjects, although none of the volunteers had titres above the protec-
tive threshold.
H5N1 Vaccine Study in Humans and Ferrets
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Fig 3. The kinetics and long-term single radial haemolysis antibody response induced after vaccination. The kinetics (A) and long-term (B) single
radial haemolysis response to the homologous vaccine strain A/Vietnam/1194/2004 (NIBRG-14) after vaccination with two doses (21 ±1 days apart) of
inactivated virosomal H5N1 vaccine alone (30μg HA, blue) or 1.5 (red), 7.5 (green) or 30 μg HA (black) adjuvanted with Matrix-M (50μg). The sampling day
after vaccination is shown on the x-axis. Each symbol represents the geometric mean lysis zone area (mm2) for one individual participant, with the group
geometric mean and 95% confidence interval presented. The dotted line shows the seroprotective SRH Zone area of25mm2.
doi:10.1371/journal.pone.0131652.g003
H5N1 Vaccine Study in Humans and Ferrets
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The kinetics and cross-reactivity of the haemagglutination inhibition
antibody response to vaccination
The kinetics of the HI response against the homologous vaccine strain (NIBRG-14) following
vaccination is shown in Fig 4A. A seroprotective response was defined as an HI titre32. No
pre vaccination HI antibody titres were detected in any of the volunteers. The NIBRG-14-spe-
cific HI antibody titres started to increase at 7 days post vaccination in all groups, except the
lowest adjuvanted dose. By day 14, an increase in the NIBRG-14-specific HI response was
detected in all vaccine groups and the titres continued to increase up to day 21. On day 21, a
majority of subjects (66%) in the 30μg HA adjuvanted group (GMT = 34) were seroprotected.
The second vaccine dose enhanced the NIBRG-14-specific HI responses in all vaccine groups.
Among the responding subjects, significantly higher HI GMTs were observed in the adjuvanted
30μg HA group compared with the non-adjuvanted group at days 28 and 42 post-vaccination.
A majority of subjects immunized with one of the adjuvanted vaccines (75% to 93%) had sero-
protective HI response after the second vaccination (between days 28 and 35), whilst during
the same period, between 54% and 64% in the vaccine alone group were seroprotected. By day
42, similar GMTs were observed in the 1.5μg (GMT = 56) and 7.5μg (GMT = 53) HA adju-
vanted groups showing the potential of Matrix M adjuvant to dose spare.
The HI assay was used to examine the kinetics of the post-vaccination response to three
other H5N1 strains; clade 1 virus A/Cambodia/R0405050/2007 (NIBRG-88, Fig 4B, clade 1.1),
and clade 2 viruses A/Indonesia/5/2005 (RG2, clade 2.1.3.2, Fig 4C) and A/turkey/Turkey/1/05
(NIBRG-23, clade 2.2.1 Fig 4D). No cross-reactive pre-vaccination HI antibodies were detected
in any of the volunteers, except to A/Indonesia/5/2005 where one subject in the 30μg HA viro-
somal group had a pre vaccination antibody titre of 32 which did not boost after vaccination.
Following the first dose, the strongest cross-reactive HI response was observed against the
NIBRG-88 strain, with HI titres peaking at 14 days post-vaccination in all four vaccinated
groups, which then plateaued until day 21. By day 21 post-vaccination, 13% to 40% of vacci-
nees were seroprotected against NIBRG-88 and most of these were in the 30μg HA adjuvanted
group. A similar response was observed against the NIBRG-23 strain with 13% to 35% of vol-
unteers having protective HI titres at day 21 post-vaccination and most of these were in either
the 30μg HA adjuvanted or virosomal alone groups. After the first dose, the lowest HI titres
were detected against the RG2 strain with only 10 volunteers (across all four vaccine groups)
having HI antibody titres32 at day 21 post-vaccination. The second vaccine dose augmented
the cross-reactive response and it generally peaked on day 35 with 64% of volunteers in the
30μg HA group having protective responses against NIBRG-23 (GMT = 39), NIBRG-88
(GMT = 43) and RG2 (GMT = 29) strains. In contrast, at day 35, only 23% to 54% of the sub-
jects in the non-adjuvanted group had protective titres against NIBRG-23 (GMT = 13),
NIBRG-88 (GMT = 19) and RG2 (GMT = 13). The day 42 HI responses were similar to that
observed on day 35 with 57%-64% of volunteers in the adjuvanted 30μg HA group having sero-
protection against NIBRG-88 (GMT = 43), NIBRG-23 (GMT = 29) and RG2 (GMT = 23). In
contrast, only 14 to 43% of volunteers in the virosomal alone group had protective responses
against NIBRG-88 (GMT = 14), NIBRG-23 (GMT = 9) and RG2 (GMT = 13) at day 42. Impor-
tantly, after two doses of the vaccine (day 42), the number of subjects who failed to induce a
cross-H5 clade HI response (non-responders) was lower in the adjuvanted 30μg HA group
(26% to 36%) compared with the non-adjuvanted vaccine (43% to 64%).
Longevity of the haemagglutination inhibition response to vaccination
Fig 5A shows the NIBRG-14-specific HI responses at days 180 and 365 post-vaccination. On
day 180, the 45% of subjects in the adjuvanted 30μg HA (GMT = 23) and 29% in the 7.5μg HA
H5N1 Vaccine Study in Humans and Ferrets
PLOS ONE | DOI:10.1371/journal.pone.0131652 July 6, 2015 10 / 22
Fig 4. The kinetics of the haemagglutination inhibition antibody response induced after vaccination.
The kinetics of the haemagglutination inhibition (HI) antibody response to the homologous vaccine strain (A)
A/Vietnam/1194/2004 (NIBRG-14) and the cross-H5 clade HI responses to (B) A/Cambodia/R0405050/2007
(NIBRG-88), (C) A/Indonesia/5/2005 (RG2) and (D) A/turkey/Turkey/1/2005 (NIBRG-23) strains were
measured by the HI assay. Subjects were vaccinated with two doses (21 ±1 days apart) of inactivated
H5N1 Vaccine Study in Humans and Ferrets
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(GMT = 10) groups were seroprotected, whilst in the 1.5μg HA group, two persons (21%) had
a seroprotective response (GMT = 6). In the virosomal alone vaccine group, 23% of subjects
had HI titres32 (GMT = 8). At 12 months after vaccination, only two volunteers from the
adjuvanted 30μg HA group and one from the 7.5μg HA had seroprotective HI titres. Fig 5B
shows that generally no long term protective HI responses were observed against the other
H5N1 strains, except four persons (across all four vaccinated groups) were seroprotected
against NIBRG-88 and two against NIBRG-23 strains at 6 months post vaccination. No cross-
H5 clade HI responses were observed at 12 months post-vaccination (data not shown).
The H5N1-specific serum IgG response
Fig 6 shows the serum NIBRG-14-specific IgG response after vaccination. Very low NIBRG-
14-specific antibody levels were observed prior to vaccination.
In comparison to day 0, an increase in the IgG response was detected in all vaccine groups
by days 14 and 21, with the adjuvanted 30μg HA group having significantly higher responses
than the non-adjuvanted group. The second dose (day 28) did not boost the IgG response in
any group except in the adjuvanted 7.5μg HA group, however this was not statistically signifi-
cant compared with day 21 levels. After the second dose, the highest IgG levels were observed
in the adjuvanted 30μg HA group, which had a significantly higher IgG response than the non-
adjuvanted vaccine at 28, 35 and 42 days post-vaccination. Among the adjuvanted groups, a
dose response was observed with significantly higher IgG levels detected in the adjuvanted
30μg HA group compared to that in the 1.5μg HA group after the first and second vaccinations.
At six and 12 months post-vaccination, the serum IgG levels in each of the vaccine groups were
significantly lower compared with that at day 42.
The correlation between homologous and cross-H5 clade serological
responses
To test whether subjects who had high NIBRG-14-specific serological responses (HI, SRH, MN
and serum IgG) also had good cross-H5 clade HI responses, we performed Spearman rank cor-
relation coefficient (r) analysis at 21, 42 and 180 days post-vaccination (Fig 7). Subjects that
had higher NIBRG-14-specific HI, SRH, MN and IgG responses also had good HI responses to
NIBRG-23 and NIBRG-88 strains with Spearman r values ranging between 0.36 and 0.7. The
correlation between the homologous serological responses and HI responses to the RG2 strain
were less robust. On day 21, the RG2-specific HI response showed a significant correlation
with the homologous HI response (r = 0.49, p<0.0001) but not with the SRH, MN or IgG
responses. However, by day 42, a significant correlation was observed between the NIBRG-
14-specific HI, SRH, MN and IgG responses and the RG2-specific HI responses, with Spear-
man r values ranging between 0.38 and 0.48. At six months post-vaccination, the NIBRG-
14-specific HI responses showed significant correlation with the NIBRG-23 and NIBRG-
88-specific HI responses, but not with RG2-specific HI titres.
virosomal H5N1 vaccine alone (30μg HA, blue) or 1.5 (red), 7.5 (green) or 30μg HA (black) adjuvanted with
Matrix-M (50μg). The sampling day after vaccination is shown on the x-axis. The HI titres were measured by
the modified HI test using horse erythrocytes. Each symbol represents the geometric HI titre for one
individual, with the group geometric mean and 95% confidence interval presented. The dotted line shows the
protective HI titre of 32.
doi:10.1371/journal.pone.0131652.g004
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Fig 5. The longevity of the haemagglutination inhibition antibody response induced after vaccination. A: The haemagglutination inhibition (HI)
response against the homologous vaccine strain A/Vietnam/1194/2004 (NIBRG-14) at 180 and 365 days after vaccination. B: The cross-H5 clade HI
response to A/turkey/Turkey/1/2005 (NIBRG-23), A/Indonesia/5/2005 (RG2) and A/Cambodia/R0405050/2007 (NIBRG-88) at 180 days post-vaccination.
Subjects were vaccinated with two doses (21 ±1 days apart) of inactivated virosomal H5N1 vaccine alone (30μg HA, blue) or 1.5 (red), 7.5 (green) or 30 μg
HA (black) adjuvanted with Matrix-M (50μg). The HI titres were measured by the modified HI test using horse erythrocytes. Each symbol represents the
geometric HI titre for one individual participant, with geometric mean titres for the group and 95% confidence interval presented. The dotted line shows the
protective HI titre of 32.
doi:10.1371/journal.pone.0131652.g005
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The antibody secreting cell response
No or very low NIBRG-14-specific ASCs were detected prior to vaccination (data not shown).
Fig 8 shows the homologous and cross-H5 clade IgG, IgA and IgM ASC responses after the
first (day 7) and second (day 28) vaccine doses. On day 7, the strongest IgG, IgA and IgM ASC
responses against both the homologous and cross-reactive strains were detected in the groups
that received the adjuvanted high dose (7.5 and 30μg HA) vaccines. After the second dose (day
28), the strongest ASC responses were observed in the group that received the adjuvanted
1.5μg HA vaccine and the ASC responses were dominated by IgG while very low IgA and IgM
levels were detected.
Memory B cell responses
We evaluated the long-term homologous Bmem response in 7–8 randomly selected volunteers
from each vaccine group at day 365 post-vaccination (Fig 9). There was a trend towards higher
NIBRG-14 virosome-specific Bmem frequencies in subjects vaccinated with the adjuvanted
7.5 μg and 30μg HA than in virosomal alone group (mean of 2264, 1475 and 632 Bmem per
1 × 106 PBMC, respectively).
Protective efficacy of the H5N1 vaccine in ferrets
The protective efficacy of the NIBRG-14 virosomal vaccine was confirmed in a ferret challenge
model of influenza infection. In this study, animals were vaccinated twice (14 days apart) mim-
icking a shorter vaccination schedule, which could be appropriate in a pandemic scenario.
Following the first vaccination, HI titres40 were detected in one animal each from the
adjuvanted 7.5 and 30μg HA groups (Fig 10A). After the second dose, the majority of ferrets
Fig 6. The H5N1-specific IgG response after vaccination. An ELISA was used to measure the NIBRG-14 influenza vaccine-specific serum IgG response
before and after vaccination. Subjects were vaccinated with two doses (21 ±1 days apart) of inactivated virosomal H5N1 vaccine alone (30μg HA, blue) or 1.5
(red), 7.5 (green) or 30μg HA (black) adjuvanted with Matrix-M (50μg). The bars represent the mean IgG titre ± standard error of the mean.
doi:10.1371/journal.pone.0131652.g006
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(70–90%) in the adjuvanted vaccine groups had HI titres40, whilst no HI responses were
observed in the unadjuvanted vaccine or control groups. After the virus challenge, 80–100% of
animals in the adjuvanted vaccine and 60% in the unadjuvanted vaccine groups had HI titres
above the protective threshold.
Three days after the virus challenge, 4 animals from each group were sacrificed and the
lung, nasal turbinate, brain, olfactory bulb and spleen samples were collected and viral titres
determined (Fig 10B). Significantly low mean viral loads were detected in the lung, brain and
spleen samples obtained from vaccinated ferrets compared with that from control animals.
Lower mean virus titres were also detected in the nasal turbinate samples from vaccinated ani-
mals compared with controls although this difference was not statistically significant. In the
olfactory bulb samples, significantly lower mean virus titres were detected in ferrets vaccinated
with the adjuvanted 7.5 and 30μg HA vaccines compared with control animals.
The remaining 6 ferrets in each group were monitored daily for 14 days for body weight and
clinical signs of disease post-challenge. Fig 10C shows the body weight of the ferrets was moni-
tored for 14 days post viral challenge. In vaccinated ferrets, the body weights remained stable
with minor fluctuations during the two-week period and all the animals survived the virus
challenge. In the control group, the body weights decreased from day 2 with only 1 animal sur-
viving the virus challenge to 14 days post-challenge. Control ferrets were sacrificed in a mori-
bund condition (2 animals each on days 5 and 6, 1 ferret on day 10) due to signs of severe
clinical infection and/or excessive weight loss.
Fig 7. Correlation between serological responses to the homologous and cross-reactive H5N1 strains
at days 21, 42 and 180 after vaccination. The correlation between A/Vietnam/1194/2004 (NIBRG-14)-
specific HI, SRH, MN and IgG responses and the HI responses against A/turkey/Turkey/1/2005 (NIBRG-23),
A/Cambodia/R0405050/2007 (NIBRG-88) and A/Indonesia/5/2005 (RG2) at 21, 42 and 180 days after
vaccination. Volunteers were divided into four vaccine groups and were vaccinated with two doses (21 ±1
days apart) of inactivated virosomal H5N1 vaccine alone (30μg HA) or 1.5, 7.5 or 30μg HA adjuvanted with
Matrix-M (50μg). Data from the four vaccine groups were combined to calculate the Spearman rank
correlation coefficient (r) value (adjusted for multiple comparisons) for each association between the
homologous and cross-H5 clade serological response. Abbreviations: p, Two-tailed p value (95% confidence
interval); NS, no significant correlation.
doi:10.1371/journal.pone.0131652.g007
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Fig 9D shows the body temperatures post-virus challenge. All the control animals developed
fever (temperature rise>1°C) within 1–2 days after viral challenge. Ferrets that received the
adjuvanted 7.5μg HA vaccine did not develop fever during the two-week period. Ferrets vacci-
nated with the adjuvanted 1.5μg HA and non-adjuvanted vaccines developed fever one week
post-challenge, but the temperatures returned to baseline levels after two weeks. Greater tem-
perature fluctuations were observed in ferrets that received the adjuvanted 30μg HA vaccine,
however the temperature returned to pre-challenge levels two weeks after vaccination. Statisti-
cal analysis of the temperatures five days after challenge, which was the last time point at which
all the animals in the control group were alive, showed that the mean body temperatures in the
adjuvanted 7.5 μg and 30μg HA vaccine groups were significantly lower than that of control
group. Furthermore, the maximum observed temperature increase in the 7.5μg HA group was
significantly lower than for the control group (p<0.004).
Discussion
Correlates of protection against avian influenza are not established and there is a need for
more detailed analysis of the kinetics, quality and magnitude of the immune response after can-
didate pandemic vaccination. In this study, we report in detail the early kinetics and the long-
term persistence of the homologous and cross-reactive immune responses after vaccination
with a candidate H5N1 influenza vaccine formulated with or without the Matrix M adjuvant.
Fig 8. The antibody secreting cell response induced after influenza vaccination. Lymphocytes were collected 7 days after the first (day 7) and second
vaccine dose (day 28) of inactivated virosomal H5N1 vaccine alone or formulated 1.5, 7.5 or 30μg HA formulated with Matrix-M (50μg). The influenza-specific
IgG, IgA and IgM antibody secreting cells (ASC) were enumerated using the ELISPOT assay. The data are presented as the mean number of influenza-
specific ASC per 200 000 lymphocytes ± standard error of the mean to the homologous vaccine strain A/Vietnam/1104/2004 (NIBRG-14), and the
heterologous responses to A/Turkey/Turkey/1/05 (NIBRG-23), A/Cambodia/R0405050/2007 (NIBRG-88) and A/Anhui/1/05 (RG6). Statistical differences
between the adjuvanted and non-adjuvanted groups were calculated by ANOVA with Dunnett’s multiple comparisons test. *p<0.05.
doi:10.1371/journal.pone.0131652.g008
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Overall, analysis of the longitudinal data using a mixed model shows that formulation with the
Matrix M adjuvant significantly enhanced (P<0.05) the serological (HI, SRH, MN) and IgG
responses against H5N1 influenza viruses (S1 Table).
Vaccination is still the best means of combating an eventual pandemic caused by a HPAI
H5N1 virus. Our findings, using the three commonly used serological assays (HI, SRH and
MN) revealed a low antibody response against NIBRG-14 after the first vaccination (days 7
and 14), with only a few subjects mainly in the adjuvanted 7.5 and 30μg HA groups having pro-
tective responses. Three weeks after the first dose, 66% and 47% of subjects in the 30μg adju-
vanted group had protective titres by HI and SRH assays, respectively, however only 7% had
protective MN titres. This may reflect the different sensitivities of the serological assays and is
in contrast to previous studies where higher sensitivities were reported for MN compared to
the HI assay (reviewed by [18]). Our HI titres are comparable with that observed after a single
dose of H5 vaccines adjuvanted with oil-in-water adjuvants, but higher than HI titres elicited
by alum-adjuvanted H5 vaccines [11, 19–21]. This is consistent with observations from a num-
ber of clinical trials where alum failed to greatly improve the immune responses to split virus
influenza vaccines in humans (reviewed by [3]).
The second vaccine dose greatly improved the protective antibody responses to the NIBRG-
14 virus as measured by the HI, SRH and MN assays, but no significant increase was detected
in the H5N1 specific serum IgG response. The day 42 NIBRG-14-specific serological responses,
which were strongest in the adjuvanted 30μg HA group, were comparable to those observed in
Fig 9. Thememory B cell (Bmem) response 365 days after vaccination. Subjects were vaccinated with
two doses (21 ±1 days apart) of inactivated virosomal H5N1 vaccine alone (30μg HA, blue) or 1.5 (red), 7.5
(green) or 30μg HA (black) adjuvanted with Matrix-M (50μg). The Bmem response at 365 days post-first
vaccination was analyzed by ELISPOT. The bars represent the mean number of NIBRG-14-specific Bmem per
1×106 peripheral blood mononuclear cells (PBMC) ± standard error of the mean.
doi:10.1371/journal.pone.0131652.g009
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adult subjects after two doses of oil-in-water adjuvanted H5 vaccines [11, 19, 22, 23], but sub-
stantially higher than an alum adjuvanted vaccine [20] or a high dose (90μg HA) non-adju-
vanted A/Vietnam/1203/2004 vaccine [24]. These results highlight the need for appropriate
adjuvant formulation of H5 influenza vaccines for enhancing immunogenicity and the superi-
ority of the Matrix M adjuvant over more traditional adjuvants such as alum. The seroprotec-
tion rates fell significantly by six months, although the adjuvant appeared to extend the
longevity of the protective responses in some subjects, as was the case in other H5N1 influenza
vaccine trials [11, 20]. By 12 months after primary vaccination, almost all subjects had NIBRG-
14-speciific HI, SRH and MN titres below the protective thresholds. Interestingly, we detected
long-term H5N1-reactive Bmem cells in all vaccine groups at day 365. Bmem cells can be rapidly
reactivated upon infection or secondary immunization and differentiate into plasma cells pro-
ducing high avidity antibodies [25]. Bmem cells may also recognize viral escape mutants more
effectively than long-lived plasma cells [26]. Maintenance of serological memory plays an
important role in combating secondary and tertiary waves of disease that may occur during a
pandemic.
The humoral immune response was further characterized by determining the kinetics of the
serum IgG (ELISA) and ASC (ELISPOT) responses. The NIBRG-14-specific serum IgG
Fig 10. Protective efficacy of the H5N1 vaccine in ferrets. Ferrets were divided into five groups of 10 and were vaccinated intramuscularly with two doses
(14 days apart) of virosomal vaccine alone (30μg HA, blue) or 1.5 (red), 7.5 (green) and 30μg HA (black) adjuvanted with Matrix M (50μg). Control ferrets
(brown) received PBS. Fourteen days after the second immunization, ferrets were challenged by administering A/Vietnam/1203/2004 live virus (106 EID50 in
0.4 mL PBS/BSA). (A) The serum HI antibody response 12 days after each vaccination with NIBRG-14 virosomal vaccine and fourteen days following
challenge with A/Vietnam/1203/2004 virus. (B) The virus titres in the nasal washing and tissue samples after challenge with the A/Vietnam/1203/2004 virus.
The limit of detection in TCID50 assay for the ferret tissue samples was 10
1.63TCID50/ml of homogenate. (C) The changes in weight and (D) temperature after
challenge with A/Vietnam/1203/2004 live virus.
doi:10.1371/journal.pone.0131652.g010
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response peaked after the first dose (day 21), but by 6 months, the titres were similar to pre-
vaccination levels. Despite the low long-term IgG titres, we have recently observed that the H5
HA1-specific IgG avidity continues to rise and was highest at 6–12 months post-vaccination
[27]. The NIBRG-14-specific ASC response in all groups, except in subjects vaccinated with
1.5μg HA peaked at day 7, which has previously been shown to correspond with the peak plas-
mablast (CD19+CD20-CD27highCD38high) response [14]. Although we did not sample a time
point before day 7, we believe this to be the peak response based on our previous observations
with trivalent seasonal [13], pandemic H1N1 [28] and candidate H7N1 [29] influenza vaccine
studies in humans. The NIBRG-14-specific IgG ASC response in the 1.5μg HA group peaked
at day 28, however as we only sampled day 28, we cannot rule out an earlier peak after the sec-
ond dose. The magnitude of the day 7 NIBRG-14-specific IgG and IgA ASC response is similar
to the response detected after vaccination with an alum-adjuvanted H7N1 vaccine, but sub-
stantially lower than observed after seasonal influenza vaccination in primed adults [13, 29,
30]. The weak NIBRG-14-specific ASC and serological responses (HI, SRH and MN) at day 7
may be explained by the fact that humans are generally not primed by previous exposure to
avian H5N1 viruses. Therefore naïve subjects may only have a small repertoire of cross-reactive
memory B cell pool that can be rapidly reactivated after vaccination. Interestingly, a relatively
strong NIBRG-23-specific IgG ASC response at day 7 may suggest a memory response against
this strain. Furthermore, the dose-dependent increase in IgM ASC responses (day 7) observed
in groups given an adjuvanted vaccine also suggests activation of a naïve B cell response against
the H5N1 viruses after vaccination.
H5N1 viruses continue to circulate in wild birds on three continents and based on phyloge-
netic characterization and sequence homology in the H5 HA gene, a number of distinctive
H5N1 virus subgroups (clades) have been identified [31, 32]. The wide geographical spread
and the considerable antigenic diversity of H5N1 viruses are significant challenges for pan-
demic preparedness, as effective vaccines need to elicit broadly cross-reactive antibody
responses to heterologous strains. Our data demonstrated a significant HI response against the
NIBRG-88 (clade 1.1) and NIBRG-23 (clade 2.2.1) strains in the group that received the adju-
vanted 30ug HA vaccine. Similar improvements in cross-clade antibody responses have been
observed with H5N1 vaccines adjuvanted with MF59 and AS03 compared with non-adju-
vanted formulations [33, 34]. Together with clade 1 (NIBRG-14), the 1.1 and 2.2.1 phylogenetic
sub-clades have caused human infections or are in current circulation, hence induction of
immunity against these strains is highly relevant. The weakest cross-reactive HI response was
observed against the RG-2 strain (clade 2.1.3.2) and this may reflect greater differences in the
sequence homology between the HA of NIBRG-14 and RG-2 strains. Importantly, the peak
cross-reactive HI responses were observed one week after the second dose. Induction of an
early cross-reactive response is important, as we cannot predict which H5N1 strain will cause
disease if a pandemic emerged. The long-term (six month) antibody response was poor even
after formulation with the adjuvant, which is consistent with previous observations [34].
Administering a third (booster) H5 vaccine dose may induce longer lasting cross-reactive
immune response as has been shown in several studies (reviewed by [3]). The cross-clade
response was further analysed in the ELISPOT assay to measure ASC and to our knowledge,
this is the first report showing cross-H5 clade ASC responses in humans after pandemic H5N1
vaccination.
Ferrets are a natural influenza host and represent a well-established model for influenza
research (reviewed by [9]). The virosomal vaccine was tested in ferrets to investigate the num-
ber of doses and time required for inducing a protective immune response against HPAI H5N1
challenge. Vaccination reduced febrile responses, severe weight loss and prevented the local
and systemic spread of the virus. Similarly, recent studies have shown that two doses of AS03
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or MF59-adjuvanted H5N1 vaccines induce protective immune responses in ferrets and reduce
virus shedding in the upper respiratory tract [35, 36]. The reduced virus shedding as observed
in our and other studies could be an important factor in limiting the horizontal transmission of
the virus to susceptible hosts. We observed that two doses of the H5 vaccine in combination
with the Matrix M adjuvant was required to induce high levels of HI antibody titres and protect
the animals from morbidity and mortality associated with the highly pathogenic avian influ-
enza virus challenge. Mathematical modeling has shown that induction of a protective immune
response within two weeks after the outbreak of influenza pandemic is required for maximal
reduction in viral transmission [37]. Collectively, this data suggest that ideally the population
should be vaccinated twice, at least four weeks before the emerging pandemic wave in order to
achieve protective immunity and minimize virus transmission.
In conclusion, we have shown that the virosomal H5N1 vaccine provides protection against
highly pathogenic avian influenza virus challenge in a ferret model. In humans, the H5N1 vac-
cine induced an early and persistent immune response that was enhanced by the addition of
the Matrix M adjuvant. Combining the H5N1 vaccine with the Matrix M adjuvant resulted in
broader cross-H5 clade immune responses. Results presented in this paper add to the existing
evidence [5, 7, 8, 38] that shows the great potential of the Matrix M adjuvanted virosomal
H5N1 vaccine.
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